Want to see TSE:KETA full AI Analyst Report?
Top Page
TripSitter Clinic Ltd
(KETA)
Select Model
Select Model
Rating:38Underperform
Price Target:
C$0.06
▼(-67.89% Downside)
Action:Downgraded
Date:02/15/26
The score is driven primarily by very weak financial performance (near-zero revenue, ongoing losses, negative equity, and continued cash burn), which outweighs any near-term technical oversold signals. Valuation is also unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Reduced cash burn
Free cash flow losses have materially narrowed versus the very large outflows in FY2022–FY2024. A smaller absolute cash burn improves runway and reduces near-term refinancing urgency, increasing the odds management can execute a restructuring or revenue restart over months.
Negative Factors
Revenue collapse
Revenue near zero eliminates operating scale and renders gross margins and unit economics non-informative. With minimal sales, fixed costs and selling efforts cannot be absorbed, making sustainable profitability dependent on a material and durable revenue reboot or significant restructuring.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced cash burn
Free cash flow losses have materially narrowed versus the very large outflows in FY2022–FY2024. A smaller absolute cash burn improves runway and reduces near-term refinancing urgency, increasing the odds management can execute a restructuring or revenue restart over months.
Read all positive factors
TripSitter Clinic Ltd (KETA) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$3.31M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-14.48
Revenue GrowthN/A
EPS Growth98.15%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding17,396,345
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-0.36
Price to Sales (P/S)0.00
P/FCF Ratio-5.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TripSitter Clinic Ltd Business Overview & Revenue Model
Company Description
TripSitter Clinic Ltd. operates a consultative virtual clinic and tele-health platform that connects patients to a licensed physician who can evaluate for a prescribed treatment program of low-dose oral ketamine medication in the United States. It...
How the Company Makes Money
null...
TripSitter Clinic Ltd Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Apr 2024 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 13.97K | 488.30K | 87.22K | 0.00 |
| Gross Profit | 0.00 | 0.00 | -4.70K | 138.71K | -554.60K | 0.00 |
| EBITDA | -4.64K | -9.61K | -348.48K | -1.85M | -10.22M | -177.59K |
| Net Income | -4.64K | -9.61K | -304.86K | -1.87M | -26.11M | -179.33K |
Balance Sheet | ||||||
| Total Assets | 598.00 | 1.20K | 2.83K | 99.27K | 1.46M | 780.68K |
| Cash, Cash Equivalents and Short-Term Investments | 598.00 | 1.20K | 2.83K | 54.85K | 1.30M | 772.39K |
| Total Debt | 389.11K | 339.62K | 273.05K | 133.50K | 133.50K | 17.88K |
| Total Liabilities | 816.44K | 748.57K | 730.57K | 548.82K | 197.59K | 93.36K |
| Stockholders Equity | -815.84K | -747.37K | -727.74K | -449.55K | 1.26M | 687.32K |
Cash Flow | ||||||
| Free Cash Flow | -55.19K | -46.52K | -201.59K | -1.39M | -1.76M | -92.97K |
| Operating Cash Flow | -55.19K | -46.52K | -201.59K | -1.39M | -1.76M | -92.97K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 2.30M | 0.00 |
| Financing Cash Flow | 53.66K | 54.91K | 139.54K | 136.43K | 16.16K | 865.37K |
TripSitter Clinic Ltd Technical Analysis
Positive
0.19
Price Trends
0.19
Positive
0.18
Positive
0.14
Positive
Market Momentum
<0.01
Positive
66.47
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KETA, the sentiment is Positive. The current price of 0.19 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 66.47 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:KETA.
TripSitter Clinic Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$509.85M | 67.12 | 2.79% | ― | 53.79% | 29.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$12.90M | -1.99 | 64.52% | ― | 7.63% | -106.03% | |
44 Neutral | C$56.20M | -2.12 | -444.52% | ― | 415.06% | -54.80% | |
42 Neutral | C$11.23M | -2.24 | 6239.15% | ― | ― | 68.00% | |
38 Underperform | C$3.31M | -19.19 | 8.34% | ― | ― | 98.15% |
* Healthcare Sector Average
TSE:KETA
TripSitter Clinic Ltd
0.19
0.13
192.31%
TSE:VHI
Vitalhub
7.96
-3.52
-30.66%
TSE:AIDR
Rocket Doctor AI
0.57
-0.12
-17.39%
TSE:CHS
Comprehensive Healthcare Systems Inc
0.45
-0.05
-11.00%
TSE:UDOC
UniDoc Health Corp
0.09
-0.11
-55.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.